Login to Your Account



Amylin, Lilly to Share Development Costs of Exenatide Pen Device

By Catherine Hollingsworth


Friday, May 1, 2009
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to develop a pen device for delivering exenatide to diabetics, an arrangement in which they will share the initial capital investment of about $216 million, with Lilly making 60 percent of that investment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription